ADVISORY, June 22, 2007 (PRIME NEWSWIRE) --
What: Dr. Isaac Cohen, L.Ac., O.M.D., Chairman and CEO, and Dr. Mary Tagliaferri, M.D., President and Chief Medical Officer of Bionovo, Inc. (BNVI) will preside over the closing bell. Where: NASDAQ MarketSite - 4 Times Square - 43rd & Broadway - Broadcast Studio When: Monday, June 25, 2007 at 4:00 p.m. ET Contacts: Jim Stapleton, CFO (510) 420-4180; jim@bionovo.com Media contact: Katherina Audley (415) 847-7295; katherina.audley@bionovo.com NASDAQ MarketSite: Jolene Libretto; 646.441.5220; mobile - 347.219.9539 Jolene.Libretto@NASDAQ.com
Feed Information:
The closing bell is available from 3:50 p.m. to 4:05 p.m. on uplink IA-6 C-band/transponder 17. The downlink frequency is 4040 Vertical; Audio 6.2-6.8 The feed can also be found on Waterfront fiber 1623. If you have any questions, please contact Jolene Libretto at (646) 441-5220.
Radio Feed:
An audio transmission of the closing bell is also available from 3:50 p.m. to 4:05 p.m. on uplink IA6 C band / transponder 24, downlink frequency 4180 horizontal. The feed can be found on Waterfront fiber 1623 as well.
Webcast:
A live webcast of the NASDAQ Closing Bell will be available at: http://www.nasdaq.com/reference/marketsite_about.stm.
Photos:
To obtain a hi-resolution photograph of the Market close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.
About Bionovo, Inc. (BNVI)
Bionovo is a drug development company focusing on the discovery of novel pharmaceutical agents for cancer and women's health. The company has two drugs in clinical testing. MF101 has completed Phase 2 for quality of life conditions associated with menopausal symptoms and in a trial of 217 postmenopausal women, MF101 at 10 grams/day was more effective than placebo at reducing hot flashes. In addition, MF101 was proven to be extremely safe and very well tolerated. BZL101 is in Phase 1/2 for the treatment of advanced breast cancer. The company has an additional pipeline of drugs in development for breast cancer, pancreatic cancer and other menopausal symptoms. Bionovo is developing its products in close collaboration with leading U.S. academic research centers, including: University of California, San Francisco, University of California, Davis, and the University of Colorado Health Sciences Center. For further information please visit: http://www.bionovo.com.